Inventia Healthcare Recalled Generic Chlorthalidone Tablets
The FDA classified the recall of over 13,000 bottles as Class II due to failed dissolution specifications.
Updated on Sept. 19, 2026 in Healthcare
Live Poll
Do you trust the quality and safety standards of generic medications produced by overseas manufacturers?
Inventia Healthcare Limited initiated a nationwide recall of 13,567 bottles of 25-milligram generic chlorthalidone tablets on Sept. 3, 2026. The FDA officially classified this action as a Class II recall on Sept. 17, 2026.
Why it matters
The recall was prompted by the medication failing to meet dissolution specifications, which means the active ingredient may not absorb properly in the body. This follows a previous recall of 11,460 bottles of the same drug conducted by the company in June 2026.
The recalled units consist of 25-milligram tablets packaged in containers of 100 tablets each. This is the second instance of chlorthalidone supply issues for the manufacturer this year.
The players
Inventia Healthcare Limited
This is an India-based pharmaceutical manufacturer that produces generic medications for the global market.
FDA
The Food and Drug Administration is the United States federal agency responsible for regulating food, tobacco, and medical products.
The details
The drug failed to meet necessary dissolution benchmarks during testing, impacting how the medication is absorbed. Inventia Healthcare Limited is overseeing the nationwide retrieval of these units.
Timeline
June 2026: Inventia Healthcare Limited recalled 11,460 bottles of chlorthalidone.
Sept. 3, 2026: The current recall of 13,567 bottles was officially initiated.
Sept. 17, 2026: The FDA classified the recall as a Class II action.
Market Landscape
This recall reflects a broader trend of increased regulatory scrutiny regarding generic drug quality and supply chain consistency. It highlights the ongoing challenges manufacturers face in maintaining strict dissolution standards across large-scale production runs.
Patients currently taking 25-milligram generic chlorthalidone should check their medication bottles and consult their healthcare provider regarding potential impacts on their treatment. If a supply shortage occurs due to this recall, pharmacists may offer alternative generic formulations or provide guidance on switching manufacturers.
The takeaway
Patients should verify their prescription lot numbers with their pharmacy to determine if their specific medication is part of the recalled batches. Always consult a medical professional before stopping a prescribed blood pressure medication to avoid health complications.
Further reading
For more information on industry standards and regulatory actions, visit the Healthcare section.
Source note: This article includes information reported by Theepochtimes.
Live Poll
Do you trust the quality and safety standards of generic medications produced by overseas manufacturers?
